IntraOp Medical

IntraOp Medical Corporation, founded in 1993, develops and manufactures electron therapy devices for cancer treatment. The company's business is centered on providing compact and mobile linear accelerators that allow oncologists to deliver precise and affordable radiation therapy directly at the point of care. Its primary clients are leading hospitals, university research centers, and specialized cancer clinics across North America, Europe, and Asia. IntraOp generates revenue through the sale of its medical devices and likely through associated services, maintenance, and support for its global installed base.

A significant milestone in the company's history was the completion of a sale in October 2013 to an investment group led by Firsthand Technology Value Fund, a publicly-traded venture capital fund. This transaction followed a restructuring process and effectively took the formerly publicly-traded company private, providing it with a clean balance sheet and capital for growth. A notable figure in its more recent history is Derek T. DeScioli, who served as CEO and led the company out of bankruptcy, steering it towards significant revenue growth and an expanded product portfolio before he departed in 2021. His leadership, backed by an engineering degree from Rutgers University and a Master's from MIT, was pivotal in establishing partnerships with world-renowned clinical research partners.

The company's flagship product is the Mobetron®, the first mobile, self-shielded electron linear accelerator (LINAC) designed to deliver Intraoperative Radiation Therapy (IORT). FDA-approved in 1998, the Mobetron allows a concentrated dose of radiation to be administered directly to the tumor site during surgery. This approach significantly shortens treatment cycles, often reducing weeks of conventional therapy to a single two-minute session, while minimizing radiation exposure to surrounding healthy tissues and organs. Its portability is a key feature, as it can be moved between existing operating rooms, eliminating the substantial cost for hospitals to build specially shielded radiation vaults. IntraOp has also advanced its technology to include ultra-high dose rate (UHDR) capabilities for FLASH radiotherapy studies, partnering with top academic institutions to explore this next frontier in cancer treatment.

Keywords: Intraoperative Radiation Therapy, IORT, electron therapy, Mobetron, linear accelerator, LINAC, cancer treatment, radiation oncology, medical devices, self-shielded LINAC, portable radiation therapy, FLASH radiotherapy, UHDR, cancer surgery, non-invasive cancer treatment, dermatology electron therapy, oncology technology, radiation therapy equipment, particle therapy, point-of-care radiation